key: cord-0715095-ytdz29qh authors: Wei, Jin; Alfajaro, Mia Madel; DeWeirdt, Peter C.; Hanna, Ruth E.; Lu-Culligan, William J.; Cai, Wesley L.; Strine, Madison S.; Zhang, Shang-Min; Graziano, Vincent R.; Schmitz, Cameron O.; Chen, Jennifer S.; Mankowski, Madeleine C.; Filler, Renata B.; Ravindra, Neal G.; Gasque, Victor; de Miguel, Fernando J.; Patil, Ajinkya; Chen, Huacui; Oguntuyo, Kasopefoluwa Y.; Abriola, Laura; Surovtseva, Yulia V.; Orchard, Robert C.; Lee, Benhur; Lindenbach, Brett D.; Politi, Katerina; van Dijk, David; Kadoch, Cigall; Simon, Matthew D.; Yan, Qin; Doench, John G.; Wilen, Craig B. title: Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection date: 2020-10-20 journal: Cell DOI: 10.1016/j.cell.2020.10.028 sha: 513ba4dc514219973b8527040d42bd607b9fa097 doc_id: 715095 cord_uid: ytdz29qh Identification of host genes essential for SARS-CoV-2 infection may reveal novel therapeutic targets and inform our understanding of COVID-19 pathogenesis. Here, we performed genome-wide CRISPR screens in Vero-E6 cells with SARS-CoV-2, MERS-CoV, bat coronavirus HKU5 expressing the SARS-CoV-1 spike, and VSV expressing the SARS-CoV-2 spike. We identify known SARS-CoV-2 host factors including the receptor ACE2 and protease Cathepsin L. We additionally discovered pro-viral genes and pathways including HMGB1 and the SWI/SNF chromatin remodeling complex that are SARS-lineage and pan-coronavirus specific, respectively. We show HMGB1 regulates ACE2 expression and is critical for viral entry of SARS-CoV-2, SARS-CoV-1, and NL63. We also show that small molecule antagonists of identified gene products inhibited SARS-CoV-2 infection in monkey and human cells, demonstrating the conserved role of these genetic hits across species. Together this identifies potential therapeutic targets for SARS-CoV-2 and reveals SARS-lineage specific and pan-coronavirus host factors that regulate susceptibility to highly pathogenic coronaviruses. -SARS-CoV-2 -rcVSV-SARS-CoV-2-S -HKU5-SARS-CoV-1-S -MERS-CoV Virus: Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 , represents the greatest public health threat in a century. More than 35,000,000 people have been infected with more than 1,000,000 deaths globally (Dong, Du and Gardner, 2020) . Novel therapeutics and vaccines are desperately needed. Coronaviruses are enveloped, positive-sense RNA viruses with genomes of approximately 30 kb that exhibit broad host-range among birds and mammals and are typically transmitted via the respiratory route (Li, 2016; Cui, Li and Shi, 2019) . There are four circulating seasonal coronaviruses in humans (NL63, OC43, 229E, and HKU1) and three highly pathogenic zoonotic coronaviruses (SARS-CoV-1, SARS-CoV-2, and Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)), none of which have effective antiviral drugs or vaccines (Guan et al., 2003; Drosten, Kellam and Memish, 2014; Tang et al., 2015; Gordon et al., 2020) . Viral entry, the first stage of the coronavirus life cycle, is mediated by the viral spike protein. The receptor binding domain of the spike binds to a specific cell surface receptor, a major determinant of host range and cell tropism (Letko, Marzi and Munster, 2020; Shang et al., 2020) . SARS-CoV-1, SARS-CoV-2, and NL63 use angiotensinconverting enzyme 2 (ACE2) while MERS-CoV uses dipeptidyl peptidase-4 (DPP4) as a receptor (Li et al., 2003; Hofmann et al., 2005; Raj et al., 2013; Letko, Marzi and Munster, 2020) The coronavirus spike protein requires two proteolytic processing steps prior to entry. The first cleavage event can occur in the producer cell, the extracellular environment, or in the endosome and can be mediated by several proteases including Furin and TMPRSS2 (Hoffman, Kleine-Weber and Pöhlmann, 2020; Walls et al., 2020; J o u r n a l P r e -p r o o f Yan et al., 2020; Zang et al., 2020) . The second proteolytic event, which exposes the viral fusion peptide, can occur at the target cell plasma membrane by TMPRSS2 or in the endosome by Cathepsin L (Hoffmann et al., 2020; Ou et al., 2020) . Upon viral membrane fusion, the viral RNA is released into the cytoplasm where it is translated and establishes viral replication and transcription complexes before assembling and budding (Snijder et al., 2006; Stertz et al., 2007; Knoops et al., 2008) . The host genes that mediate these processes remain largely elusive. Identification of host factors essential for infection is critical to inform mechanisms of coronavirus pathogenesis, reveal variation in host susceptibility, and identify novel host-directed therapies, which may have efficacy against current and future pandemic coronaviruses. To reveal host genes required for SARS-CoV-2 infection and cell death, we performed genome-wide CRISPR screens with SARS-CoV-2, SARS-CoV-1, and MERS-CoV in a Chlorocebus sabaeus (African green monkey or vervet) cell line, Vero-E6. Vero-E6 cells have several distinct advantages for SARSlineage and MERS-CoV genetic screening. First, Vero-E6 cells and African green monkeys are susceptible to both SARS-lineage (SARS-CoV-1 and SARS-CoV-2) and MERS-CoV enabling direct comparisons across all three highly pathogenic coronaviruses (Clay et al., 2012; Matsuyama et al., 2020; Ogando et al., 2020; Totura et al., 2020; Woolsey et al., 2020) . Second, Vero-E6 cells endogenously express ACE2 and DPP4 which enables the discovery of novel regulators of receptor expression. This may not be possible with a transgenic cell line that over-expresses ACE2 or DPP4 under an exogenous promoter (Heaton et al., 2020) . Importantly, cigarette smoking both upregulates ACE2 expression and represents a risk factor for severe J o u r n a l P r e -p r o o f highlighting the importance of uncovering the determinants of ACE2 regulation (Smith et al., 2020) . Third, unlike other coronavirus susceptible cell lines (e.g. Huh7.5), SARSlineage and MERS-CoV infection of Vero-E6 cells is more cytopathic which enables screening at a later stage of the viral life cycle than would be possible based on screening for expression of a virus-encoded protein or reporter. Notably, Vero-E6 cells do not express type I interferon. While this may preclude identification of some genes, it also provides a reductionist system that may reduce potential bias towards interferonstimulated genes (Desmyter, Melnick and Rawls, 1968; Emeny and Morgan, 1979; Chew et al., 2009) . Our screens identified the protease Cathepsin L for both SARS-lineage and MERS-CoV and the viral receptors ACE2 and DPP4, for SARS-lineage viruses and MERS-CoV, respectively. We identified genes that are SARS-CoV-2-specific, MERS-CoV-specific, and pan-coronavirus-specific, and determined that the majority of genes which regulate SARS-CoV-2 infection acted at the level of viral entry. We performed pooled and individual validation of the top CRISPR gene hits. Specifically, we identified HMGB1 and the SWI/SNF chromatin remodeling complex as pro-viral. We found that HMGB1 is critical for ACE2 expression and viral entry of SARS-CoV-1, SARS-CoV-2, and NL63, all of which use ACE2 as a receptor. In contrast, several SWI/SNF complex members were critical for viral entry of both SARS-lineage and MERS-CoV but not influenza A virus (IAV) or encephalomyocarditis virus (EMCV), demonstrating specificity for coronaviruses rather than a broadly acting anti-viral phenotype. We demonstrated that small molecule antagonists of pro-viral gene products inhibit SARS-CoV-2 infection J o u r n a l P r e -p r o o f of Vero-E6 and human cells in vitro. These hits represent novel therapeutic targets for SARS-CoV-2 and enhance our understanding of COVID-19 pathogenesis. Discovery of host genes and pathways that mediate pathogenesis of pandemic coronaviruses is a critical resource that may promote our understanding of how these viruses cause disease, why there is variable host susceptibility, the origins of host species range, and may reveal host-directed therapeutic targets against both known and unknown coronaviruses of pandemic potential. To identify host factors essential for cell survival in response to pandemic human coronaviruses including SARS-CoV-1, SARS-CoV-2 and MERS-CoV, we used Vero-E6 cells, a model cell line for isolating viruses that were selected based on their susceptibility and cytopathic effects in response to all three pandemic CoVs (Matsuyama et al., 2020; Ogando et al., 2020; Woolsey et al., 2020) . We performed genome-wide CRISPR screens with SARS-CoV-2 (isolate USA-WA1/2020), MERS-CoV (EMC/2012), a tissue culture-adapted MERS-CoV (T1015N), and a recombinant bat coronavirus (HKU5) containing the spike protein of SARS-CoV-1 (HKU5-SARS-CoV-1-S) (Scobey et al., 2013; Agnihothram et al., 2014) . HKU5-SARS-CoV-1-S was used as a surrogate for SARS-CoV-1, which is a select agent. Further, to test whether genes implicated in SARS-CoV-2 infection acted at the level of viral entry, we performed a genome-wide screen with replication competent vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike protein (rcVSV-SARS-CoV-2-S). rcVSV-SARS-CoV-2-S is deficient for the broadly fusogenic VSV J o u r n a l P r e -p r o o f glycoprotein (G), and thus, viral entry is entirely mediated by the SARS-CoV-2 spike protein (Case et al., 2020; Dieterle et al., 2020) We used a C. sabaeus genome-wide pooled CRISPR library composed of 83,963 targeting single guide RNAs (sgRNAs), with an average of four sgRNAs per gene, and 1,000 non-targeting control sgRNAs. We initially performed two independent SARS-CoV-2 genome-wide screens with Vero-E6 lines expressing two different Cas9 nuclease constructs (Cas9-v1 and Cas9-v2); Cas9-v2 has an additional nuclear localization sequence to increase activity. We transduced both Vero-Cas9 cell lines with the C. sabaeus sgRNA library and challenged cells with SARS-CoV-2 ( Figure 1A ). To generate a robust dataset, we performed independent screens at different cell densities, fetal bovine serum (FBS) concentrations, and multiplicities of infection (MOI). Z-scores for all SARS-CoV-2 screens are in Table S1 . Subsequent MERS-CoV WT, MERS-CoV T1015N, HKU5-SARS-CoV-1-S, and rcVSV-SARS-CoV-2-S screens were performed in duplicate under a single cell density, FBS concentration, and MOI. Genomic DNA was harvested from surviving cells at 7-9 days post-infection (dpi) and guide abundance was determined by PCR and massively parallel sequencing. Technical performance of the screens is described in STAR Methods and Figure S1 . The SARS-CoV-2 screen identified numerous genes that confer either resistance (pro-viral) or sensitization (anti-viral) when targeted by sgRNAs, with a minimum FDR of 0.03 for non-targeting controls ( Figure 1B -C), demonstrating high technical quality. The strongest resistance hit was the viral receptor ACE2 (mean z-score = 4.9; descending rank = 1; Figure 1B -C and S2A-B). CTSL, which encodes the Cathepsin L protease, was also positively selected in all conditions (mean z-score = 3.0; descending rank = J o u r n a l P r e -p r o o f 18; Figure 1B -C and S2B). We did not observe enrichment of TMPRSS2 (mean z-score = 0.9; descending rank = 2726) nor the proteases TMPRSS4 or FURIN (mean z-scores = 1.1, 0.4; descending ranks = 1657, 7180, respectively), which have also been implicated in SARS-CoV-2 entry (Hoffmann et al., 2020; Shang et al., 2020; Zang et al., 2020) , suggesting these proteases are either not essential in a cell-intrinsic manner for SARS-CoV-2-induced cell death as performed herein and/or are functionally redundant. Comparison of SARS-CoV-2 to rcVSV-SARS-CoV-2-S revealed substantial concordance between the viruses, suggesting that concordant genes act at the level of viral entry ( Figure 1C -D). SARS-CoV-2 and HKU5-SARS-CoV-1-S screens also yielded similar overlap consistent with similar mechanisms of entry as mediated by the SARS-CoV-1 and SARS-CoV-2 spike proteins ( Figure 1E ). Next, we assessed the relationship between MERS-CoV and SARS-CoV-2 screens. The MERS-CoV receptor DPP4 was the top resistance hit in the MERS-CoV screen, whereas ACE2 was not enriched ( Figure 1F ). SARS-CoV-2 resistance genes ARID1A, DYRK1A, KDM6A, and CTSL were also highly enriched in the MERS-CoV screen ( Figure 1F ). Pairwise correlations of all genome-wide screens are shown in Figure S3 and z-scores for all genes are shown in Table S2 . Next, we compared the top 100 resistance genes across the genome-wide screens with SARS-CoV-2, rcVSV-SARS-CoV-2-S, HKU5-SARS-CoV-1-S, and MERS-CoV (WT) viruses. Five genes (ARID1A, KDM6A, JMJD6, SMARCC1, and CTSL) scored in each of the four virus screens. That these genes were enriched in the SARS-CoV-2, HKU5-SARS-CoV-1-S, and MERS-CoV (WT) screens suggest they are potentially pan-coronaviral. Because they also were enriched in the rcVSV-SARS-CoV-2-S screen, they act at the level of coronavirus entry ( Figure 1G ). Together this J o u r n a l P r e -p r o o f suggests these genes promote lineage-independent entry of pandemic coronaviruses. showing enrichment (mean z-scores = 3.6, 2.8, 2.4, 2.3, descending ranks = 9, 20, 47, 59, respectively; Figure 2B ). The SWI/SNF complex is an ATP-dependent nucleosome remodeling complex that regulates chromatin accessibility and gene expression (Zhou et al., 2016; Clapier et al., 2017) . Interestingly, while SWI/SNF complex genes ARID1A, SMARCB1, and SMARCC1 were enriched in both SARS-lineage and MERS-CoV screens, SMARCA4 was only enriched in the SARS-lineage screens. We also identified several other histone modifying enzymes as key regulators of SARS-CoV-2-induced cell death ( Figure 1C and S2B). Other pro-viral genes include the histone demethylase KDM6A (mean z-score = 4.1; descending rank = 4), histone methyltransferase KMT2D (mean z-score = 2.6; descending rank = 35), as well as the lysyl hydroxylase JMJD6 (mean z-score = 3.7; descending rank = 6) ( Figure 1C and S2B) (Webby et al., 2009; Hu et al., 2013; Unoki et al., 2013; Chakraborty et al., 2019) . In contrast, sgRNAs targeting HIRA, CABIN1, and ASF1A were negatively selected, revealing an anti-viral function. These genes encode three of the four proteins in the HUCA histone H3.3 chaperone complex (mean z-scores = -5.7, -5.4, -3.0; ascending ranks = 1, 2, 64, respectively), suggesting an anti-viral role for the deposition of the histone variant H3.3 (Rai et al., 2011) . We additionally observed enrichment in the "RUNX3 regulates CDKN1A transcription" gene set from Reactome (Figure 2A and C). This is driven by enrichment of sgRNAs targeting the signal transducers SMAD3 and SMAD4 (mean z-scores = 2.8, 3.1; descending ranks = 21, 15, respectively). The "cystatin and endolysosome lumen" gene set which includes CTSL was also enriched ( Figure 2D ). Unsurprisingly, we observed the enrichment of "Viral translation" in both positive and negative directions J o u r n a l P r e -p r o o f ( Figure 2E ). The NURF complex was the top gene set enriched in the negative direction ( Figure 2F ). To validate the genome-wide screens, we generated a custom CRISPR subpool containing 10 sgRNAs for each of the top 250 and bottom 250 genes from an earlier analysis of the SARS-CoV-2 screen along with 500 non-targeting control sgRNAs and sgRNAs targeting other genes of interest such as the MERS-CoV receptor, DPP4. We introduced this sgRNA library into Vero-Cas9-v2 cells and challenged this pool with either SARS-CoV-2, rcVSV-SARS-CoV-2-S, HKU5-SARS-CoV-1-S, MERS-CoV, or MERS-CoV T1015N. We included the orthomyxovirus Influenza A virus (A/WSN/1933) (IAV), the picornavirus EMCV, and VSV (Indiana) as control viruses, which all cause cytopathic effects in Vero-E6 cells. All eight viruses were screened in duplicate except for IAV. The secondary screen validated the top pro-viral and anti-viral genes from the primary genome-wide SARS-CoV-2 screen ( Figure 3A and Table S3 ). Clustering the correlations between the log2-fold changes of each condition revealed that the viruses containing a SARS-lineage spike grouped together, as did MERS-CoV WT and T1015N, whereas IAV and EMCV were outliers, as expected ( Figure 3B ). A principal component analysis of the secondary screens revealed clusters of gene hits in an unbiased manner ( Figure 3C ). Focusing on the top resistance hits for each virus screen, we saw SARS-lineage specific (e.g. ACE2, PHIP), MERS-lineage specific (e.g. DPP4) and pan-coronaviruses specific genes (e.g. CTSL, ARID1A, PCBD1 and KMT2D) J o u r n a l P r e -p r o o f ( Figure S4A ). Consistent with the genome-wide CRISPR screens, the key genes encoding members of the SWI/SNF complex are pro-viral for coronaviruses but not IAV or EMCV ( Figure S4B ). We observed SMAD3 and SMAD4 were modestly enriched in the SARS-CoV-2 and rcVSV-SARS-CoV-2-S subpool screens ( Figure S4C ). In addition, the top sensitization genes involved in the HUCA histone H3.3 chaperone complex were specific to the SARS-lineage spike protein ( Figure S4D To begin to understand the generalizability of these hits to human cells, we screened a small CRISPR subpool targeting 32 genes in Calu-3 cells, a lung adenocarcinoma line that natively expresses ACE2 (Table S4 ). This screen revealed significant overlap in both pro-viral (including ACE2, DYRK1A, SMARCA4, KDM6A, JMJD6, SMARCE1 andSIAH1) and anti-viral genes (including HIRA, PIAS2 and SMARCA5) between Vero-E6 and Calu-3 cells ( Figure 3I ), suggesting the conserved role of these genetic hits across species. Notably, TMPRSS2 but not CTSL was J o u r n a l P r e -p r o o f enriched in the Calu-3 subpool screen, consistent with TMPRSS2 expression in Calu-3 cells but not Vero-E6 cells (Böttcher-Friebertshäuser et al., 2011) . We selected 25 genes for further validation of the SARS-CoV-2 screen in an arrayed rather than pooled format, consisting of 18 resistance and 7 sensitization genes ( Figure 4A ). We transduced Vero-Cas9-v2 cells with one of 42 individual sgRNAs (1 to 3 sgRNAs per gene). We then challenged each of the 42 cell lines with SARS-CoV-2 and assessed cell viability. Cells receiving sgRNAs targeting pro-viral genes exhibited greater viability than those with non-targeting control sgRNAs. We validated the knockout efficiency of several genes (including ACE2, SMARCA4, KDM6A and SMAD3) by western blot, and the protein abundance correlated with the degree of protection ( Figure 4B -D). Cells receiving sgRNAs targeting anti-viral genes in the primary screen exhibited increased susceptibility to cell death relative to controls, confirming the efficiency and reproducibility of the screen ( Figure 4B and D). The robust concordance between the primary screens and the several subsequent validation approaches indicates that these screens will be a useful resource for further investigation of coronavirus host pathogen interactions. Next, we asked whether the genes and pathways revealed by the screen could be targeted with small molecules. We selected antagonists previously described to inhibit these gene products and investigated their effects on SARS-CoV-2-induced cell death. In addition, we utilized a replication competent infectious clone of SARS-CoV-2 expressing the fluorescent reporter mNeonGreen (icSARS-CoV-2-mNG) to quantify the J o u r n a l P r e -p r o o f influence of these molecules on viral replication (Xie et al., 2020) . We observed dosedependent inhibition of SARS-CoV-2-induced cell death and virus replication with Calpain Inhibitor III, whose targets include Cathepsin L ( Figure 5A , 5D-E) (Simmons et al., 2005; Hoffmann et al., 2019) . Given the pro-viral role of SMARCA4 and SMAD3, we tested whether existing small molecule antagonists of these pathways have antiviral activity against SARS-CoV-2. Specifically, treatment with PFI-3, which targets the bromodomains of the SWI/SNF proteins SMARCA4 and SMARCA2 (Fedorov et al., 2015; Xie et al., 2020) , conferred protection from virus-induced cell death ( Figure 5B ) and reduced frequency of viral infection, as measured by expression of mNeonGreen ( Figure 5D -E). We also assessed the small molecule SIS3 which targets the pro-viral gene SMAD3 identified in the screen (Jinnin, Ihn and Tamaki, 2006) . SIS3 exhibited dose-dependent protection from virus-induced cell death and also inhibited SARS-CoV-2 fluorescent reporter expression ( Figure 5C -E). We next performed SARS-CoV-2 growth curves to investigate the effects of PFI-3 and SIS3 in Vero-E6, Calu-3, and the human liver cell line, Huh7.5. We observed a ~1-log reduction in PFI-3-treated cells and ~2-log reduction in SIS3-treated cells ( Figure 5F -H). This provides pharmacological validation in Vero-E6 and human cells in addition to genetic evidence that these pathways are critical to SARS-CoV-2 infection. The SARS-CoV-2 screen revealed a putative pro-viral role for the gene LOC103214541, which is annotated as "HMGB1-like" in the C. sabaeus genome (mean J o u r n a l P r e -p r o o f z-score = 3.6, descending rank = 10; Figure 1C and 6A). HMGB1 is a nuclear protein that binds DNA but translocates to the cytoplasm under conditions of stress and can be secreted extracellularly where it functions as an alarmin (Andersson, Yang and Harris, 2018) . HMGB1-like was also identified as pro-viral in the rcVSV-SARS-CoV-2-S and HKU5-SARS-CoV-1-S but not the MERS-CoV screens ( Figure 1C , G and Figure 3C -E). To validate the role of HMGB1 in SARS-CoV-2 infection, we introduced two independent sgRNAs targeting HMGB1 into each of three independent cell lines: Vero-E6, Huh7.5, and Calu-3 cells. We observed depletion of HMGB1 protein as measured by western blot ( Figure 6B ). HMGB1 disruption protected cells from SARS-CoV-2induced cell death, and the degree of protection correlated with HMGB1 protein abundance ( Figure 6C ). We then performed SARS-CoV-2 growth curves on control and HMGB1-disrupted cells and observed a ~2-log reduction in SARS-CoV-2 replication at both 24 and 48 hours post-infection ( Figure 6D ). Next we investigated whether HMGB1 is acting cell-intrinsically or acting as an alarmin to regulate SARS-CoV-2 infection. SARS-CoV-2 infection increased HMGB1 protein levels in the nucleus and cytoplasm ( Figure S5A ) and culture media ( Figure S5B -C). Recombinant HMGB1 protein had no effect on SARS-CoV-2 infection when added extracellularly to either WT or HMGB1 KO cells as measured by cell viability, icSARS-CoV-2-mNG infection, and SARS-CoV-2 pseudovirus infection ( Figure S5D -F), demonstrating that HMGB1 is acting cellintrinsically, rather than as an alarmin or chemokine, to regulate SARS-CoV-2 infection. As HMGB1 is a DNA binding protein that regulates chromatin, we hypothesized that HMGB1 controls a pro-viral gene expression program. When we compared differentially expressed genes between control and HMGB1 disrupted cells with the J o u r n a l P r e -p r o o f gene-level z-scores from the genome-wide CRISPR screen, we found that among proviral genes only HMGB1, ACE2 and CTSL gene expression was significantly downregulated in HMGB1 disrupted cells ( Figure 6E and S6A). Interestingly, few other differentially expressed genes were enriched in either the positive or negative direction in the CRISPR screen. We confirmed ACE2 transcripts were significantly reduced in HMGB1 knockout cells compared to WT Vero-E6 cells by quantitative PCR (RT-qPCR), as were ACE2 protein levels by western blot ( Figure 6F ). Gene Ontology enrichment analysis indicated 16 gene sets were significantly enriched in differentially expression genes; however, these gene sets were not enriched in the SARS-CoV-2 CRISPR screen ( Figure S6B ). We next analyzed the effects of HMGB1 disruption on chromatin states across the genome by chromatin immunoprecipitation sequencing (ChIP-seq) and assay for transposase-accessible chromatin sequencing (ATAC-seq; Figure S6C -D). Upon HMGB1 disruption, changes in chromatin accessibility by ATAC-seq were positively correlated with changes in H3K27ac ChIP-Seq, a marker of active enhancers ( Figure S6E ), as expected. ChIP-seq revealed significant reduction in H3K27ac level (p=0.01) at a peak immediately downstream from the ACE2 transcription start site in HMGB1 disrupted cells compared to control cells ( Figure 6G and S6D). In addition, we observed a trend towards reduced chromatin accessibility at the overlapping ATAC-seq peak at the ACE2 locus (p=0.057) in HMGB1 disrupted cells compared to control cells ( Figure 6G and S6C). HMGB1 is necessary for ACE2 expression, as well as viral entry of SARS-CoV-1, SARS-CoV-2, and NL63, but not MERS-CoV which mirrors receptor J o u r n a l P r e -p r o o f utilization ( Figure 6F and H). Taken together, these findings demonstrate that HMGB1 is a novel regulator of ACE2 expression which affects susceptibility to SARS-CoV-2. We performed the first genome-wide screens for host genes that affect infection by pandemic coronaviruses SARS-CoV-2 and MERS-CoV as well as the recombinant bat coronavirus HKU5-SARS-CoV-1-S. The identification of the viral receptors ACE2 and DPP4 and protease CTSL demonstrate the technical quality of the screens, providing confidence in the additional genes that regulate SARS-CoV-2 infection (Hoffmann et al., 2019 (Hoffmann et al., , 2020 Ou et al., 2020; Shang et al., 2020) . We discovered genes involved in diverse biological processes including chromatin remodeling, histone modification, cellular signaling, and RNA regulation. We validated key genes in both a pooled and arrayed format, including both pro-viral and anti-viral genes, and identified small molecule antagonists that confer protection to SARS-CoV-2-induced cell death and infection in Vero-E6, human hepatocytes, and human lung cells. Our screen identified many genes with functional roles in chromatin regulation and histone modification which highlight the potential importance of epigenetic regulation of pathogenic coronavirus infection. Epigenetic processes have previously been implicated in regulating antigen presentation and interferon-stimulated gene induction after MERS-CoV and SARS-CoV-1 infection (Menachery et al., 2014 (Menachery et al., , 2018 Schäfer and Baric, 2017) ; however, given that Vero-E6 cells are type I interferondeficient, distinct mechanism(s) may be at play. Interestingly, the majority of both proviral and anti-viral genes identified function at the level of viral entry as determined by the high degree of concordance between SARS-CoV-2 and rcVSV-SARS-CoV-2-S screens. We identified both ACE2 dependent and independent mechanisms regulating coronavirus entry. Specifically, we identify a novel epigenetic role for HMGB1 in regulating ACE2 expression and thus susceptibility to SARS-CoV-1, SARS-CoV-2, and NL63. We demonstrate this both in Vero-E6 cells and two human IFN-sufficient cell lines. HMGB1 is a pleiotropic protein that binds nucleosomes regulating chromatin in the nucleus, acts as a sentinel of non-self nucleic acids, transports genetic material, and functions as a secreted alarmin in response to virus infection (Menachery et al., 2014; Andersson, Ottestad and Tracey, 2020; Simpson et al., 2020) . Interestingly, anti-HMGB1 therapies can reduce respiratory syncytial virus replication and IAV-induced lung pathology in animal models (Manti et al., 2018; Hatayama et al., 2019) , while in adenovirus infection, the viral protein VII binds HMGB1 and inhibits its proinflammatory functions (Avgousti et al., 2016) . Notably, we find that HMGB1 regulates ACE2 expression in a cell-intrinsic manner and not via its function as a cytokine or alarmin, suggesting a distinct mechanism of HMGB1 in SARS-CoV-2 infection. Genes encoding members of the SWI/SNF chromatin remodeling complex were identified as pro-viral for SARS-CoV-2, MERS-CoV, and HKU5-SARS-CoV-1-S, suggesting this complex is broadly important for pathogenic coronaviruses. These genes were also identified as pro-viral for rcVSV-SARS-CoV-2-S suggesting a role for SWI/SNF complexes in promoting coronavirus entry. The SWI/SNF complex is comprised of a catalytic ATPase subunit, either SMARCA2 or SMARCA4, and a larger, non-catalytic protein scaffold core that is bridged to the ATPase via ARID1A (Mashtalir et al., 2018) . SWI/SNF complexes lack intrinsic DNA sequence specificity and thus their targeting specificity is conferred by DNA-binding proteins, which bind and recruit them to genomic target sites where they then slide and eject nucleosomes regulating J o u r n a l P r e -p r o o f chromatin accessibility and gene expression. We speculate that the pro-viral role of SWI/SNF complexes may be opposed by the histone H3.3 (HUCA chaperone) complex, which has been shown to co-target with SWI/SNF complexes on chromatin (Pchelintsev et al., 2013) . The pro-viral and anti-viral genes identified herein have important implications for our understanding of COVID-19 pathogenesis, therapeutics, and vaccine design. First, SARS-CoV-2 can cause diverse phenotypes ranging from asymptomatic infection to severe respiratory failure and death (Wang et al., 2020; Zhu et al., 2020) . The basis for this variation among people and between species is unclear. The genes and pathways identified here may explain this variation as disease susceptibility may positively correlate with expression of resistance genes and negatively correlate with sensitization genes on the cellular, tissue, and organismal level. For example, cigarette smoking both increases ACE2 expression and exacerbates COVID-19 pathogenesis (Smith et al., 2020) . The regulatory network underlying this is unknown, but it is intriguing to speculate that the chromatin and histone modifying genes identified here contribute to expression of a heterogeneous pro-viral gene expression program that potentially regulates ACE2 and other viral interacting genes. In addition, despite Vero-E6 cells being deficient in interferon, we identified the interferon-stimulated gene LY6E as an anti-viral entry factor for both SARS-lineage and MERS-CoV. This suggests basal expression of LY6E in the absence of type I interferon and is consistent with a recent study identifying Ly6E as a pan-coronavirus anti-viral molecule (Pfaender et al., 2020) and reveals the utility and applicability of Vero-E6 cells as a model system to reveal host-pathogen interactions of pathogenic coronaviruses. The genetic screen revealed novel therapeutic targets for SARS-CoV-2 infection. As a proof-of-principle, we tested several small molecule inhibitors and identified three molecules that inhibit SARS-CoV-2 replication and virus-induced cell death. Therapeutic targeting of these genes and pathways, including the SWI/SNF complex and SMAD3/SMAD4, may prove clinically useful. Additionally, we identified and validated anti-viral genes, including regulators of the histone variant H3.3 (CABIN1, HIRA, ASF1A) (Rai et al., 2011; Ray-Gallet et al., 2018) . While these genes potentially provide protection from SARS-CoV-2, they may also prove fruitful in generating knockout cell lines with increased susceptibility to diverse human coronaviruses, which may facilitate coronavirus vaccine production (Gao et al., 2020) . SARS-CoV-1, MERS-CoV, and SARS-CoV-2 reveal the pandemic potential and dangers of emerging coronaviruses for which there are no FDA-approved therapeutics or vaccines (Guan et al., 2003; Drosten, Kellam and Memish, 2014; Gordon et al., 2020) . To our knowledge this study represents the first genome-wide genetic screen performed with any human coronaviruses. Ultimately, our findings may be broadly applicable to other human and emerging coronaviruses, which may facilitate development of host-directed therapies against existing and future pandemic coronaviruses. This study identified host genes that are essential for coronavirus infection in Vero-E6 cells, and we demonstrate that HMGB1 regulates ACE2 transcription. Yet, the mechanism underlying how the majority of these genes regulate infection remains to be transcription" from Reactome, (D) "Cystatin, and endolysosome lumen" from STRING, (E) "Viral translation" from GO, (F) "NURF complex" from GO. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Craig Wilen (craig.wilen@yale.edu). All requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact author. Materials will be made publicly available either through publicly available repositories or via the authors upon execution of a Material Transfer Agreement. The published article includes all data generated or analyzed during the study except as described below. The RNA-seq (accession GSE154784), ATAC-Seq Vero-E6 and Huh7.5 cells, 5 µg/ml of puromycin (Gibco) and 5 µg/ml blasticidin (Gibco), were added as appropriate. For Calu-3 cells, 1 µg/ml of puromycin was added as appropriate. To generate viral stocks, Huh7.5 (for SARS-CoV-2) or Vero-E6 (for HKU5-SARS- Vero-E6 cells were seeded at 7.5 x 10 5 cells/well in 6-well plates or 4 x 10 5 cells/well in 12-well plates. The following day, the media was removed and replaced with 100 µl of 10-fold serial dilutions of virus. Plates were incubated at 37°C for 1 hour with gentle rocking. Subsequently, overlay media (DMEM, 2% FBS, 0.6% Avicel RC-581) was added to each well. At 2 dpi for SARS-CoV-2 and 3 dpi for other coronaviruses, plates were fixed with 10% formaldehyde for 30 min, stained with crystal violet solution (0.5% crystal violet in 20% ethanol) for 30 min, and then rinsed with deionized water to visualize plaques. Vero-E6 cells (ATCC) were transduced with lenti-Cas9 (Cas9-v1, Addgene 52962) or pLX_311-Cas9 (Cas9-v2, Addgene 96924) and selected with blasticidin (5 µg/ml) for 10 days. Table S5 . To assess technical performance, we calculated the log-fold change of each among Cas9-v1 conditions; Figure S1A ). We compared the depletion of sgRNAs targeting essential genes versus sgRNAs targeting non-essential genes in the mockinfected conditions with each Cas9 construct and observed superior performance with the Cas9-v2 construct (AUC = 0.82 vs 0.70 for Cas9-v1; Figure S1B ), although the top positively and negatively selected hits remained concordant between the two Cas9 constructs (Pearson's r = 0.24, Figure S1C ) (Hart et al., 2014 (Hart et al., , 2015 . The enhanced Cas9 activity of Cas9-v2 was confirmed with a GFP reporter assay ( Figure S1D -E). We therefore proceeded with the data from the Cas9-v2 screens and calculated a guidelevel residual (representing a log 2 fold change) between mock-infected and SARS-CoV-2 infected cells ( Figure S1F ). A positive residual indicates a gene is pro-viral and confers resistance to virus-induced cell death, while a negative residual indicates a gene is anti-viral and sensitizes a cell to virus-induced cell death. A z-score for enrichment or depletion was determined for each condition based on the distribution of residuals for all sgRNAs. We then averaged z-scores across all five Cas9-v2 screen conditions, combined p-values using Fisher's method, and calculated a false discovery rate (FDR) using the Benjamini-Hochberg procedure to identify hit genes. Tertiary CRISPR knockout library (CP1560), which contains 148 sgRNAs by targeting 32 human genes with 4 sgRNAs per gene and 20 non-targeting control sgRNAs in lentiCRISPRv2 (Addgene 52961), was delivered by lentiviral transduction of 2 x 10 6 Calu-3 cells at ~0.2 MOI. Two days post-transduction, puromycin was added to the media and transduced cells were selected for ten days. 5 x 10 5 Calu-3 cells were plated in 5% FBS media in 6-well plates and infected with SARS-CoV-2 at 0.1 MOI. At 4 dpi, 80% of the media was exchanged for fresh media. At 7 dpi, genomic DNA of surviving cells was isolated for sequencing. Guide sequences were extracted from the sequencing reads with PoolQ version 3.2.9 (Broad Institute,https://portals.broadinstitute.org/gpp/public/software/poolq), using a "CACCG" search prefix, and a counts matrix was generated. Read counts were lognormalized within each condition using the following formula: log-normalized reads per million for guide = log 2 ((# of reads for guide / total reads in condition x 1e6) + 1) Prior to analysis, any sgRNAs with an outlier abundance in the plasmid DNA pool (defined as a log-normalized read count > 3 standard deviations from the mean) or that had > 5 predicted off-target sites with a CFD score = 1 ("Match Bin I") were filtered out. This removed 755 sgRNAs; the remaining 84,208 sgRNAs were used for all analyses. We then calculated log-fold changes (LFCs) by subtracting the log-normalized plasmid DNA. For each condition, we fit a natural cubic spline with 4 degrees of freedom, using the mock infected LFCs as the independent variable and the relevant condition's LFCs as the dependent variable. We used the residual from this fit spline to represent the deviation from the expected LFC for each guide. To combine these residuals at the gene level, we calculated a z-score for each condition, z=(x-µ)/(σ/n), where x is the mean residual for a gene, µ is the mean residual of all sgRNAs, σ is the standard deviation of all sgRNAs and n is the number of sgRNAs for a given gene. We used the normal distribution function to calculate p-values from the z-scores. To combine pvalues across multiple conditions we used Fisher's method. Finally, to calculate the false discovery rate for each gene we used the Benjamini-Hochberg procedure. We J o u r n a l P r e -p r o o f used the same pDNA and off-target filters for the secondary and tertiary libraries. To analyze these libraries, we z-scored LFCs using intergenic control sgRNAs. We used the STRING enrichment detection tool to identify significantly enriched gene sets, using African green monkey gene symbols, but testing for enrichment across human gene sets. We analyzed sets from all available sources provided by that tool, including sets of clusters of protein-protein interactors in STRING, and excluding the PubMed gene sets. We then generated a network of enriched gene sets by drawing edges between sets with a significant overlap between genes. We evaluated the significance of overlap using Fisher's exact test. We clustered the network using a weighted graph, treating the fraction of genes that overlap between any sets as edge weights and proteins as nodes, weighted by the absolute value of the z-score. Then, we used the infomap algorithm (Rosvall and Bergstrom, 2008) , to cluster the network. We evaluated the centrality of each node to a given cluster using the PageRank algorithm with a damping factor of 0.5 and employing the same edge and node weights (for personalized PageRank) as we did with clustering (Brin and Page, 1998) . HMGB1 sgRNAs were cloned into lentiCRISPRv2 (Addgene 52961) which also encodes the Cas9 gene (Sanjana, Shalem and Zhang, 2014) . sgRNAs for all other genes were cloned into lentiGuide-Puro or a variant thereof, pXPR_050 (Addgene 52963, 96925, respectively). Individual sgRNAs target sequences are in Table S6 . Vero-E6-Cas9-v2 cells were individually transduced with lentiviruses expressing one to three unique sgRNA per gene and then selected with puromycin for 7 days. After selection, 1.25 x 10 3 cells were seeded in each well of a 384-well black walled clear bottom plate in 20 µl of DMEM + 5% FBS. The following day, 5 µl of SARS-CoV-2 was added for a final MOI of 0.2. Cells were incubated for three days before assessing cellular viability by CellTiter Glo (Promega). For each cell line, viability was determined in SARS-CoV-2 infected relative to mock infected cells. Five replicates per condition were performed in each of three independent experiments. Vero-E6 cells were plated at 2.5 x 10 3 cells per well in a 384-well plate and then the following day, icSARS-CoV-2-mNG was added at a MOI of 1.0 (Xie et al., 2020) . Infected cell frequencies as measured by mNeonGreen expression were assessed at 2 dpi by high content imaging (Cytation 5, BioTek) configured with bright field and GFP cubes. Total cell numbers were quantified by Gen5 software of brightfield images. Object analysis was used to determine the number of mNeonGreen positive cells. The percentage of infection was calculated as the ratio between the number of mNeonGreen+ cells and the total number of cells in brightfield. Data are normalized to the average of DMSO treated cells. Calpain Inhibitor III (#14283), SIS3 (#15495), and PFI-3 (#15267) were purchased from Cayman Chemical. Drugs were resuspended at a stock concentration of 40 mM in DMSO and then two-fold serial dilutions were performed in DMSO. 20 nl of J o u r n a l P r e -p r o o f 1000X drug stock were spotted into each well of a 384-well plate using Labcyte ECHO acoustic dispenser at the Yale Center for Molecular Discovery. 1.25 x 10 3 Vero-E6 cells were plated per well in 20 µl of phenol-red free DMEM containing 5% FBS. Two days later, 5,000 PFU (MOI ~1) icSARS-CoV-2-mNG in 5 µl media was added. Cells were incubated at 37°C and 5% CO2 for two days. Infected cell frequencies were quantified by mNeonGreen at 2 dpi (Cytation 5, BioTek). In parallel, 1000 PFU (MOI~0.2) SARS-CoV-2 in 5 µl media was added to replicate plates and cell viability was quantified by CellTiter Glo at 3 dpi. Vero-E6, Huh7.5 and Calu-3 cells were pretreated with 10 µM SIS3 and 40 µM PFI-3 for 48 hours and then infected with SARS-CoV-2 at a MOI of 0.1. Viral production was determined by plaque assay. Cytotoxicity was not observed in these cell lines during the time and concentration of drug used. Total cellular RNA was extracted using Direct-zol RNA MiniPrep Kit and submitted to the Yale Center for Genome Analysis for library preparation. RNA-seq libraries were sequenced on an Illumina NovaSeq 6000 instrument with the goal of at least 25 × 10 6 reads per sample. Reads were aligned to reference genome chlSab2, NCBI annotation release 100, using STAR aligner v2.7.3a (Dobin et al., 2013) with parameters --winAnchorMultimapNmax 200 --outFilterMultimapNmax 100 --quantMode GeneCounts. Differential expression was obtained using the R package DESeq2 v1.32 (Dobin et al., 2013; Love, Huber and Anders, 2014) . Bigwig files were generated using Cutadapt (Martin, 2011) and aligned to the reference genome chlSab2 using Bowtie2 (Langmead and Salzberg, 2012) . Alignments were filtered using SAMtools (Li et al., 2009) , and peak calls and enrichment tracks were created using MACS2 (Zhang et al., 2008) . Differential analysis at called peaks was performed using DESeq2 (Love, Huber and Anders, 2014) . Peaks were assigned to the nearest transcription start site within 100kb for integration with RNA-seq data and overlaps of ChIP-seq and ATAC-seq peaks were determined using bedtools. ATAC-seq libraries were generated following the omni-ATAC protocol as described (Corces et al., 2017) . Two biological repeats were generated per each sample. 50,000 viable cells were resuspended in 50 µl cold ATAC-Resuspension Buffer additional cycles for each sample was determined as described (Buenrostro et al., 2015) . After the final amplification, PCR reaction was purified using a Zymo DNA Clean (Bolger, Lohse and Usadel, 2014) and aligned to chlSab2 using Bowtie2 v2.2.9 (Langmead and Salzberg, 2012) with parameter -X2000. Duplicates were marked using Picard Tools v2.9.0 (Broad Institute. version 2.9.0. "Picard Tools." Broad Institute, GitHub repository. http://broadinstitute.github.io/picard/). Duplicated, unpaired, and mitochondrial reads were removed using SAMTools v1.9 (Li et al., 2009) . Reads were shifted +4 bp and -5 bp for forward and reverse strands, respectively. Peaks were called using MACS2 v2.2.6 (Zhang et al., 2008) with parameters --nomodel --keep-dup all -s 1 --shift -75 -extsize 150. Reads that fell inside peaks were counted using featureCounts v1.6.2 (Liao, Smyth and Shi, 2014) and differential accessibility analysis was performed using DESeq2 v1.32 (Love, Huber and Anders, 2014) . Bigwig files were generated using deeptools v3.1.3 (Ramírez et al., 2016) with parameter --normalizeUsing RPKM. Total RNA was isolated from cells using Direct-zol RNA MiniPrep Plus kit, reverse transcribed, and subjected to real-time PCR analysis to measure mRNA levels of tested genes. Data shown are the relative abundance of the indicated mRNA normalized to that of actin. Gene-specific primer sequences were as follows ACE2: GGGATCAGAGATCGGAAGAAGA (forward) and AAGGAGGTCTGAACATCATCAGTG J o u r n a l P r e -p r o o f (reverse); Actin: GAGCACAGAGCCTCGCCTTT (forward) and ATCATCATCCATGGTGAGCTGG (reverse). Vero-E6 cells were mock-infected or infected with SARS-CoV-2 at a MOI of 1.0 for 24 hours before cellular fractionation was performed using a Nuclear/Cytosol fractionation kit (BioVision Cat#K266-25) according to manufacturer instructions. In brief, 1 x 10 7 cells were collected by centrifugation at 600 x g for 5 min at 4°C. Add 0.2 ml Cytosol Extraction Buffer A (CEB-A) to fully resuspend the cell pellet. After 10 min incubation on ice, add 11 µl of ice-cold CEB-B and incubate on ice for 1min. Centrifuge at 16000 x g for 5 min, the supernatant was collected as cytoplasmic fraction. The pellet was resuspended in 100 µl of ice-cold Nuclear Extraction Buffer (NEB) vertex every 10 min for a total of 40 min. The samples were centrifuge at 16000 x g for 10 min, and the supernatant was collected as the nuclear fraction. Cells were collected and lysed in Nonidet P-40 lysis buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 10 mg/ml aprotinin, 10 mg/ml leupeptin, and 1 mM PMSF). The cell lysates or cellular fractions were fractionated on SDS-PAGE and transferred to a PVDF membrane. Immunoblotting analyses were performed with the indicated antibodies and visualized with horseradish peroxidasecoupled goat anti-mouse/rabbit IgG using a chemiluminescence detection system (BioRad ChemiDoc MP). J o u r n a l P r e -p r o o f Vero-E6 cells were individually transduced with lentiviruses expressing two guide RNAs targeting HMGB1 (Table S6) After an incubation period of 1 h at 37°C, the inoculum was removed and cells were washed with PBS before media supplemented with anti-VSV-G clone IE9F9 was added in order to neutralize residual input virus (no antibody was added to cells expressing VSV-G) (Lefrancois and Lyles, 1982) . Pseudotyped particles were harvested 24 hours post inoculation, clarified from cellular debris by centrifugation and stored at -80°C before use. Plasmids encoding codon-optimized form of SARS-CoV-1-S glycoprotein, MERS-CoV S∆CT and NL63 S∆CT glycoproteins lacking cytoplasmic tail were previously described J o u r n a l P r e -p r o o f (Huang et al., 2006; Letko, Marzi and Munster, 2020 Statistical significance was determined as p < 0.05 using GraphPad Prism 8 unless otherwise indicated. Experiments were analyzed by unpaired two-tailed t tests, Mann-Whitney test, or ANOVA, as indicated. Table S1 . Vero-E6 SARS-CoV-2 genome-wide CRISPR screens, Related to Figure 1 . J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f • Therapeutic targets including SMARCA4 identified for SARS-CoV-2 infection. • HMGB1 is novel regulator of ACE2 expression and critical for viral entry. To identify potential therapeutic targets for SARS-CoV-2 and related pathogenic coronaviruses, Wei et al. conduct genome-wide CRISPR screens in Vero-E6 cells using SARS-CoV-2, MERS-CoV or pseudoviruses presenting SARS-CoV-1 or -2 spike proteins. They identify pro-viral genes and pathways including HMGB1 and the SWI/SNF chromatin remodeling complex that are SARS-lineage and pan-coronavirus specific, respectively, and demonstrate that HMGB1 is critical for SARS-lineage viral entry because it plays a critical role in ACE2 expression. A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant', mBio Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?', Molecular medicine High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells A core viral protein binds host nucleosomes to sequester immune danger signals' Trimmomatic: a flexible trimmer for Illumina sequence data Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2 The anatomy of a large-scale hypertextual web search engine ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide', Current protocols in molecular biology Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies', Trends in genetics: TIG Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate Characterization of the interferon regulatory factor 3-mediated antiviral response in a cell line deficient for IFN production Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes', Nature reviews Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues Origin and evolution of pathogenic coronaviruses Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero) A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition STAR: ultrafast universal RNA-seq aligner Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9' An interactive web-based dashboard to track COVID-19 in real time Evidence for camel-to-human transmission of MERS coronavirus Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance Rapid development of an inactivated vaccine candidate for SARS-CoV-2', Science A SARS-CoV-2 protein interaction map reveals targets for drug repurposing' Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China Measuring error rates in genomic perturbation screens: gold standards for human functional genomics', Molecular systems biology High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities Combined effect of anti-high-mobility group box-1 monoclonal antibody and peramivir against influenza A virus-induced pneumonia in mice SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2 A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins', Pathogens SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum Fast gapped-read alignment with Bowtie 2' The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses featureCounts: an efficient general purpose program for assigning sequence reads to genomic features Structure, Function, and Evolution of Coronavirus Spike Proteins', Annual Review of Virology The Sequence Alignment/Map format and SAMtools Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 Induction of high-mobility group Box-1 in vitro and in vivo by respiratory syncytial virus Cutadapt removes adapter sequences from high-throughput sequencing reads Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses', mBio MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology', bioRxiv Discovery of a proteinaceous cellular receptor for a norovirus Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV' Placing the HIRA histone chaperone complex in the chromatin landscape LY6E impairs coronavirus fusion and confers immune control of viral disease Human CABIN1 is a functional member of the human HIRA/UBN1/ASF1a histone H3.3 chaperone complex Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC' deepTools2: a next generation web server for deepsequencing data analysis Functional activity of the H3.3 histone chaperone complex HIRA requires trimerization of the HIRA subunit Maps of random walks on complex networks reveal community structure Improved vectors and genome-wide libraries for CRISPR screening Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities Epigenetic Landscape during Coronavirus Infection Reverse genetics with a full-length infectious cDNA of the Proinvasion metastasis drivers in early-stage melanoma are oncogenes Cell entry mechanisms of SARS-CoV-2 Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry Respiratory Syncytial Virus Infection Promotes Necroptosis and HMGB1 Release by Airway Epithelial Cells', American journal of respiratory and critical care medicine Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex The intracellular sites of early replication and budding of SARScoronavirus Lentivirus-delivered stable gene silencing by RNAi in primary cells STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition Small Particle Aerosol Exposure of African Green Monkeys to MERS-CoV as a Model for Highly Pathogenic Coronavirus Infection', Emerging infectious diseases Lysyl 5-hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6) Structure, Function, and Antigenicity of the SARS-CoV Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China' Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing Establishment of an African green monkey model for COVID-19 An Infectious cDNA Clone of SARS-CoV-2 Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes Model-based analysis of ChIP-Seq (MACS) Mechanisms of ATP-Dependent Chromatin Remodeling Motors', Annual review of biophysics A Novel Coronavirus from Patients with Pneumonia in China We would like to acknowledge Brian Smith, Nancy Brown, and